Effect of testosterone replacement therapy on lower urinary tract symptoms: A systematic review and network meta‐analysis
Journal of Evidence-Based Medicine · 2024
DOI: 10.1111/jebm.12628 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Journal of Evidence-Based Medicine, 2024. Verfasst von Xiang Yuan und 2 weiteren Autor:innen. Beteiligte Einrichtung: Division of Thoracic Tumor Multimodality Treatment, Cancer Center, West China Hospital, Sichuan University, Chengdu, China. Hauptthemen laut MEDLINE: Hormone Replacement Therapy, Hypogonadism, Lower Urinary Tract Symptoms, Testosterone. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 46 Literaturangaben. Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Objective
In this study, we aimed to perform a network meta‐analysis (NMA) to investigate the effects of different testosterone replacement therapy (TRT) administration routes on lower urinary tract symptoms (LUTS) in aging men with late‐onset hypogonadism (LOH).
Methods
A systematic search of PubMed, Embase, The Cochrane Library, CNKI, WanFang Data, and VIP was conducted to identify randomized controlled trials (RCTs) reporting data on International Prostate Symptom Score (IPSS), prostate‐specific antigen (PSA) level, or prostate volume. NMA was performed, and subgroup analysis was conducted to assess the impact of TRT duration on outcomes.
Results
A total of 21 RCTs involving 2453 participants were included. For pairwise meta‐analysis, p values for TRT delivered by transdermal, intramuscular, and oral routes were as follows: IPSS: 0.93, 0.20, and 0.76; PSA level: 0.20, 0.27, and 0.98; prostate volume: 0.18, 0.04, and 0.16. There were no significant differences in IPSS, PSA level, or prostate volume between TRT routes. In subgroup analysis, long‐term intramuscular TRT significantly decreased IPSS ( p = 0.03), short‐term transdermal TRT increased PSA levels ( p < 0.001), and short‐term intramuscular TRT increased the prostate volume ( p = 0.04). Other forms of TRT showed no significant change in IPSS, PSA level, and prostate volume compared with the placebo. Indirect comparison of the three administration routes demonstrated no significant differences in IPSS, PSA level, and prostate volume. Nevertheless, surface under the cumulative ranking curve analysis indicated that intramuscular TRT had an 83% probability of being the best method for decreasing IPSS.
Conclusions
The results demonstrate that TRT does not worsen LUTS regardless of the administration route. Intramuscular TRT may be the preferred treatment for aging men with LOH and LUTS. Intramuscular TRT may be the preferred treatment for men with LOH and LUTS. Further research is warranted to validate these findings and optimize TRT management strategies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Thoracic Tumor Multimodality Treatment, Cancer Center, West China Hospital, Sichuan University, Chengdu, China.
- Department of Urology, West China Hospital, Sichuan University, Chengdu, China.
ORCID-Profile: Xiang Yuan
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Yuan, X., Xiong, X., & Xue, J. (2024). Effect of testosterone replacement therapy on lower urinary tract symptoms: A systematic review and network meta‐analysis. Journal of Evidence-Based Medicine. https://doi.org/10.1111/jebm.12628
Vancouver
Yuan X, Xiong X, Xue J. Effect of testosterone replacement therapy on lower urinary tract symptoms: A systematic review and network meta‐analysis. Journal of Evidence-Based Medicine. 2024. doi:10.1111/jebm.12628
BibTeX
@article{Yuan2024,
author = {Yuan, Xiang and Xiong, Xingyu and Xue, Jianxin},
title = {Effect of testosterone replacement therapy on lower urinary tract symptoms: A systematic review and network meta‐analysis},
journal = {Journal of Evidence-Based Medicine},
year = {2024},
doi = {10.1111/jebm.12628}
}
EUVIMED